Exact Sciences (EXAS) massively beat third-quarter expectations Thursday and raised its full-year outlook — and EXAS stock jumped.
During the September quarter, Exact Sciences brought in $523.1 million in sales. That handily topped projections for $502 million, according to FactSet. On a year-over-year basis, sales grew roughly 15%.
But excluding the impact of Covid tests — which have dropped off amid falling demand — revenue grew a stronger 20%, Exact Sciences said in a news release. Exact also lost 84 cents a share, narrowing from a 97-cent per-share loss in the year-earlier period. That beat estimates for another 97-cent loss.
During the regular session, EXAS stock sank 2% to 32.34. But shares climbed 4.5% higher, near 33.80, in after-hours trading on today's stock market.
EXAS Stock: Guidance Boosted By $33 Million
The results pushed Exact Sciences to boost its full-year sales outlook by $33 million. Now, the medtech company expects $2.025 billion to $2.042 billion in sales. EXAS stock analysts forecasted $2.01 billion in full-year sales.
That outlook includes $1.375 billion to $1.382 billion from its cancer screening business. Exact also calls for its precision oncology segment to bring in $595 million to $600 million in sales, and for Covid tests to generate $55 million to $60 million.
The company also said it expects adjusted earnings before interest, taxes, depreciation and amortization to be profitable in the third quarter of 2023, ahead of expectations for 2024.
https://www.investors.com/news/technology/exas-stock-exact-sciences-earnings-q3-2022/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.